Acacia Pharma is a specialty pharma company focused on the development of drugs that help patients cope with the side effects of cancer treatments, such as nausea and vomiting.
The company’s lead drug, APD421 for post-operative nausea and vomiting, launched the last clinical trial, and is now in the market registration phase. Its second project, APD403, which treats chemotherapy-induced nausea and vomiting, is in late clinical development.
Supportive care for people with cancer is a rapidly developing market, representing a $1 billion opportunity worldwide, as there is a great unmet need to improve these patients’ treatment outcomes and quality of life.
Gilde was the company’s founding investor. Acacia Pharma, based in Cambridge, UK, has since pursued an asset-centric business model and attracted other leading international healthcare investors.
Cambridge, United Kingdom